Malignant epithelial tumor of ovary

Summary

Malignant epithelial tumor of ovary (MONDO:0018364) is a cancer (an umbrella term covering 6 Mondo subtypes) with 28 cohort genes (32 GWAS associations across 5 studies; 2 CIViC-evidence somatic drivers) and 130 clinical trials. Top therapeutic interventions include lapatinib, erlotinib, and sorafenib.

At a glance

• Classification: Cancer
• Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
• Umbrella term: 6 Mondo subtypes
• Cohort genes: 28
• GWAS associations: 32
• Clinical trials: 130

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 100 000	9.39	Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant epithelial tumor of ovary
Mondo ID	MONDO:0018364
MeSH	C538090
Orphanet	398934
DOID	DOID:2151
NCIT	C40026
SNOMED CT	254849005
UMLS	C0346161
MedGen	577291
GARD	0009362
Is cancer (heuristic)	yes

Also known as: epithelial cancer of ovary · malignant ovarian epithelial tumor · malignant ovarian epithelial tumour · malignant ovarian surface epithelial-stromal neoplasm · malignant ovarian surface epithelial-stromal tumor · malignant ovarian surface epithelial-stromal tumour · ovarian epithelial cancer · ovarian epithelial tumor, malignant · ovarian malignant epithelial tumor · ovarian malignant epithelial tumour · ovarian stromal cancer

Data availability: 32 GWAS associations (5 studies) · 3 cell lines.

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › ovarian epithelial tumor › malignant epithelial tumor of ovary

Related subtypes (10): ovarian Brenner tumor, ovarian squamous cell neoplasm, ovarian mucinous neoplasm, ovarian seromucinous tumor, ovarian papillary tumor, ovarian mucinous adenofibroma, ovarian adenoma benign, borderline epithelial tumor of ovary, ovarian clear cell tumor, ovarian serous tumor

Subtypes (6): ovarian clear cell cancer, malignant ovarian Brenner tumor, ovarian endometrial cancer, ovarian carcinoma, mucinous ovarian cancer, malignant ovarian serous tumor

Genetics & variants

GWAS landscape

32 GWAS associations across 5 studies. Top hits map to 23 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs7651446	6e-51	TIPARP, TIPARP-AS1	A	1.59
rs3814113	6e-50	BNC2 - RN7SL720P	G	1.27
rs10088218	1e-20	LINC00824	A	1.3
rs9303542	5e-15	SKAP1	G	1.14
rs8170	5e-14	BABAM1, USHBP1	A	1.18
rs2072590	9e-14	HAGLR, HAGLROS	A	1.14
rs183211	2e-13	NSF	A	1.11
rs12039431	1e-11	RSPO1	?	1.11
rs11782652	3e-10	CHMP4C	G
rs1243180	1e-09	MLLT10	A	1.1
rs10069690	9e-09	TERT	A	1.14
rs8044477	1e-08	RPL12P36 - Metazoa_SRP	?	1.1
rs1413299	2e-08	COL15A1	C	1.2
rs3820282	2e-08	WNT4	?	1.11
rs17329882	2e-08	SYNPO2	?	1.09
rs757210	2e-08	HNF1B	A	1.11
rs1192691	3e-08	Y_RNA - MKNK2P1	C	1.23
rs115344852	3e-08	GPX6	?	1.1
rs11175194	1e-07	SRGAP1	G	1.19
rs4525119	5e-07	AKR1C3	C	1.43
rs7643459	8e-07	LMCD1-AS1	T	1.4
rs633862	9e-07	ABO - Y_RNA	A	1.19
rs4286604	9e-07	UGT2B4 - UGT2A2	G	1.45
rs142091544	9e-07	TENM2-AS1 - WWC1	T	3.22
rs10017134	1e-06	UGT2A1, UGT2A2	C	1.4
rs2500488	4e-06	ZBTB18 - RN7SL148P	C	1.47
rs6976769	4e-06	RAD23BP2 - SEMA3A	C	1.46

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST002748	Kuchenbaecker KB	2015	4,368	9,123	Identification of six new susceptibility loci for invasive epithelial ovarian cancer.
GCST002576	Chen K	2014	1,044	1,172	Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women.
GCST009008	Manichaikul A	2019	755	1,235	Identification of novel epithelial ovarian cancer loci in Women of African Ancestry.
GCST009896	Grant DJ	2019	755	1,235	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.
GCST002267	Earp MA	2013	84	0	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	27

MAF distribution

Bucket	Variants
common (>=0.05)	25
low_freq (0.01-0.05)	1
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intron_variant	19
intergenic_variant	6
synonymous_variant	1
non_coding_transcript_exon_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs7651446	3	156689208	G>T	0.05	intron_variant	TIPARP, TIPARP-AS1	6e-51	Tier 4: intronic/intergenic
rs3814113	9	16915023	T>C	0.32	intergenic_variant	BNC2 - RN7SL720P	6e-50	Tier 4: intronic/intergenic
rs10088218	8	128531703	G>A	0.13	intron_variant	LINC00824	1e-20	Tier 4: intronic/intergenic
rs9303542	17	48334138	A>G	0.27	intron_variant	SKAP1	5e-15	Tier 4: intronic/intergenic
rs8170	19	17278895	G>A,C,T	0.19	synonymous_variant	BABAM1, USHBP1	5e-14	Tier 4: intronic/intergenic
rs2072590	2	176177905	A>C,G,T	0.32	non_coding_transcript_exon_variant	HAGLR, HAGLROS	9e-14	Tier 4: intronic/intergenic
rs183211	17	46710944	G>A,C,T	0.24	intron_variant	NSF	2e-13	Tier 4: intronic/intergenic
rs12039431	1	37616450	G>A	0.05	intron_variant	RSPO1	1e-11	Tier 4: intronic/intergenic
rs11782652	8	81741409	A>G,T	0.07	intron_variant	CHMP4C	3e-10	Tier 4: intronic/intergenic
rs1243180	10	21626690	T>A,G	0.31	intron_variant	MLLT10	1e-09	Tier 4: intronic/intergenic
rs10069690	5	1279675	C>T	0.26	intron_variant	TERT	9e-09	Tier 4: intronic/intergenic
rs8044477	16	58942687	A>C,G	0.05	intron_variant	RPL12P36 - Metazoa_SRP	1e-08	Tier 4: intronic/intergenic
rs1413299	9	98998959	G>A,C,T	0.38	intron_variant	COL15A1	2e-08	Tier 4: intronic/intergenic
rs3820282	1	22141722	C>A,G,T	0.05	intron_variant	WNT4	2e-08	Tier 4: intronic/intergenic
rs17329882	4	119028805	A>C,T	0.05	intron_variant	SYNPO2	2e-08	Tier 4: intronic/intergenic
rs757210	17	37736525	C>A,G,T	0.37	intron_variant	HNF1B	2e-08	Tier 4: intronic/intergenic
rs1192691	10	36880367	G>A,C,T	0.46	intergenic_variant	Y_RNA - MKNK2P1	3e-08	Tier 4: intronic/intergenic
rs115344852	6	28518321			intergenic_variant	GPX6	3e-08	Tier 4: intronic/intergenic
rs11175194	12	63871057	G>A,C	0.41	intron_variant	SRGAP1	1e-07	Tier 4: intronic/intergenic
rs4525119	10	5049762	C>T	0.331	intron_variant	AKR1C3	5e-07	Tier 4: intronic/intergenic
rs7643459	3	7963141	G>C,T	0.362	intron_variant	LMCD1-AS1	8e-07	Tier 4: intronic/intergenic
rs633862	9	133279871	T>A,C	0.46	intergenic_variant	ABO - Y_RNA	9e-07	Tier 4: intronic/intergenic
rs4286604	4	69576447	A>G,T	0.268	intron_variant	UGT2B4 - UGT2A2	9e-07	Tier 4: intronic/intergenic
rs142091544	5	168286995	C>A,G,T	0.034	intergenic_variant	TENM2-AS1 - WWC1	9e-07	Tier 4: intronic/intergenic
rs10017134	4	69591303	T>A,C	0.27	intron_variant	UGT2A1, UGT2A2	1e-06	Tier 4: intronic/intergenic
rs2500488	1	244077146	C>G,T	0.33	intron_variant	ZBTB18 - RN7SL148P	4e-06	Tier 4: intronic/intergenic
rs6976769	7	83667946	A>C,G	0.05	intergenic_variant	RAD23BP2 - SEMA3A	4e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 34 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
TERT	Act	PRCC	CIViC #79
TGFBR1	LoF	ESCA

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SEMA3E	Orphanet:138	CHARGE syndrome
HNF1B	Orphanet:1309	Medullary sponge kidney
HNF1B	Orphanet:1331	Familial prostate cancer
HNF1B	Orphanet:2578	Mayer-Rokitansky-Küster-Hauser syndrome type 2
HNF1B	Orphanet:261265	17q12 microdeletion syndrome
HNF1B	Orphanet:93111	HNF1B-related autosomal dominant tubulointerstitial kidney disease
HNF1B	Orphanet:93172	Renal dysplasia, unilateral
HNF1B	Orphanet:93173	Renal dysplasia, bilateral
HNF1B	Orphanet:97363	Unilateral multicystic dysplastic kidney
HNF1B	Orphanet:97364	Bilateral multicystic dysplastic kidney
TERT	Orphanet:146	Differentiated thyroid carcinoma
TERT	Orphanet:1501	Adrenocortical carcinoma
TERT	Orphanet:1775	Dyskeratosis congenita
TERT	Orphanet:2032	Idiopathic pulmonary fibrosis
TERT	Orphanet:2495	Meningioma
TERT	Orphanet:3322	Hoyeraal-Hreidarsson syndrome
TERT	Orphanet:457246	Clear cell sarcoma of kidney
TERT	Orphanet:618	Familial melanoma
TERT	Orphanet:88	Idiopathic aplastic anemia
TGFBR1	Orphanet:284973	Marfan syndrome type 2
TGFBR1	Orphanet:60030	Loeys-Dietz syndrome
TGFBR1	Orphanet:65748	Multiple self-healing squamous epithelioma
TGFBR1	Orphanet:91387	Familial thoracic aortic aneurysm and aortic dissection
WNT4	Orphanet:139466	SERKAL syndrome
WNT4	Orphanet:247768	Müllerian aplasia and hyperandrogenism
WNT4	Orphanet:2578	Mayer-Rokitansky-Küster-Hauser syndrome type 2
ZBTB18	Orphanet:36367	Distal deletion 1q syndrome
MLLT10	Orphanet:99861	Precursor T-cell acute lymphoblastic leukemia
RSPO1	Orphanet:85112	Palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome
PLEKHM1	Orphanet:210110	Intermediate osteopetrosis
BNC2	Orphanet:93110	Posterior urethral valve
ABCB4	Orphanet:69663	Low phospholipid-associated cholelithiasis
ABCB4	Orphanet:69665	Intrahepatic cholestasis of pregnancy
ABCB4	Orphanet:79305	Progressive familial intrahepatic cholestasis type 3

Cohort genes → proteins

28 cohort genes, 27 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	28

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SEMA3E	HGNC:10727	ENSG00000170381	O15041	Semaphorin-3E	gwas
SURF6	HGNC:11478	ENSG00000148296	O75683	Surfeit locus protein 6	gwas
HNF1B	HGNC:11630	ENSG00000275410	P35680	Hepatocyte nuclear factor 1-beta	gwas
TERT	HGNC:11730	ENSG00000164362	O14746	Telomerase reverse transcriptase	gwas
TGFBR1	HGNC:11772	ENSG00000106799	P36897	TGF-beta receptor type-1	gwas
WNT4	HGNC:12783	ENSG00000162552	P56705	Protein Wnt-4	gwas
ZBTB18	HGNC:13030	ENSG00000179456	Q99592	Zinc finger and BTB domain-containing protein 18	gwas
SKAP1	HGNC:15605	ENSG00000141293	Q86WV1	Src kinase-associated phosphoprotein 1	gwas
MLLT10	HGNC:16063	ENSG00000078403	P55197	Protein AF-10	gwas
ANKRD30A	HGNC:17234	ENSG00000148513	Q9BXX3	Ankyrin repeat domain-containing protein 30A	gwas
SRGAP1	HGNC:17382	ENSG00000196935	Q7Z6B7	SLIT-ROBO Rho GTPase-activating protein 1	gwas
NAMPTP1	HGNC:17633	ENSG00000229644		nicotinamide phosphoribosyltransferase pseudogene 1	gwas
SYNPO2	HGNC:17732	ENSG00000172403	Q9UMS6	Synaptopodin-2	gwas
RSPO1	HGNC:21679	ENSG00000169218	Q2MKA7	R-spondin-1	gwas
COL15A1	HGNC:2192	ENSG00000204291	P39059	Collagen alpha-1(XV) chain	gwas
TIPARP	HGNC:23696	ENSG00000163659	Q7Z3E1	Protein mono-ADP-ribosyltransferase TIPARP	gwas
BABAM1	HGNC:25008	ENSG00000105393	Q9NWV8	BRISC and BRCA1-A complex member 1	gwas
UGT2A2	HGNC:28183	ENSG00000271271	P0DTE5	UDP-glucuronosyltransferase 2A2	gwas
PLEKHM1	HGNC:29017	ENSG00000225190	Q9Y4G2	Pleckstrin homology domain-containing family M member 1	gwas
ADSS2	HGNC:292	ENSG00000035687	P30520	Adenylosuccinate synthetase isozyme 2	gwas
WWC1	HGNC:29435	ENSG00000113645	Q8IX03	Protein KIBRA	gwas
CHMP4C	HGNC:30599	ENSG00000164695	Q96CF2	Charged multivesicular body protein 4c	gwas
BNC2	HGNC:30988	ENSG00000173068	Q6ZN30	Zinc finger protein basonuclin-2	gwas
AKR1C3	HGNC:386	ENSG00000196139	P42330	Aldo-keto reductase family 1 member C3	gwas
ABCB4	HGNC:45	ENSG00000005471	P21439	Phosphatidylcholine translocator ABCB4	gwas
GPX6	HGNC:4558	ENSG00000198704	P59796	Glutathione peroxidase 6	gwas
HOXD1	HGNC:5132	ENSG00000128645	Q9GZZ0	Homeobox protein Hox-D1	gwas
ABO	HGNC:79	ENSG00000175164	P16442	Histo-blood group ABO system transferase	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SEMA3E	Semaphorin-3E	Plays an important role in signaling via the cell surface receptor PLXND1.
SURF6	Surfeit locus protein 6	Binds to both DNA and RNA in vitro, with a stronger binding capacity for RNA.
HNF1B	Hepatocyte nuclear factor 1-beta	Transcription factor that binds to the inverted palindrome 5’-GTTAATNATTAAC-3'.
TERT	Telomerase reverse transcriptase	Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes.
TGFBR1	TGF-beta receptor type-1	Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3.
WNT4	Protein Wnt-4	Ligand for members of the frizzled family of seven transmembrane receptors.
ZBTB18	Zinc finger and BTB domain-containing protein 18	Transcriptional repressor that plays a role in various developmental processes such as myogenesis and brain development.
SKAP1	Src kinase-associated phosphoprotein 1	Positively regulates T-cell receptor signaling by enhancing the MAP kinase pathway.
MLLT10	Protein AF-10	Probably involved in transcriptional regulation.
SRGAP1	SLIT-ROBO Rho GTPase-activating protein 1	GTPase-activating protein for RhoA and Cdc42 small GTPases.
SYNPO2	Synaptopodin-2	Has an actin-binding and actin-bundling activity.
RSPO1	R-spondin-1	Activator of the canonical Wnt signaling pathway by acting as a ligand for LGR4-6 receptors.
COL15A1	Collagen alpha-1(XV) chain	Structural protein that stabilizes microvessels and muscle cells, both in heart and in skeletal muscle.
TIPARP	Protein mono-ADP-ribosyltransferase TIPARP	ADP-ribosyltransferase that mediates mono-ADP-ribosylation of glutamate, aspartate and cysteine residues on target proteins.
BABAM1	BRISC and BRCA1-A complex member 1	Component of the BRCA1-A complex, a complex that specifically recognizes ‘Lys-63’-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks…
UGT2A2	UDP-glucuronosyltransferase 2A2	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into eit…
PLEKHM1	Pleckstrin homology domain-containing family M member 1	Acts as a multivalent adapter protein that regulates Rab7-dependent and HOPS complex-dependent fusion events in the endolysosomal system and couples autophagic and the endocytic trafficking pathways.
ADSS2	Adenylosuccinate synthetase isozyme 2	Plays an important role in the de novo pathway and in the salvage pathway of purine nucleotide biosynthesis.
WWC1	Protein KIBRA	Regulator of the Hippo signaling pathway, also known as the Salvador-Warts-Hippo (SWH) pathway.
CHMP4C	Charged multivesicular body protein 4c	Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs.
BNC2	Zinc finger protein basonuclin-2	Probable transcription factor specific for skin keratinocytes.
AKR1C3	Aldo-keto reductase family 1 member C3	Cytosolic aldo-keto reductase that catalyzes NADPH-dependent reduction of ketosteroids to hydroxysteroids.
ABCB4	Phosphatidylcholine translocator ABCB4	Energy-dependent phospholipid efflux translocator that acts as a positive regulator of biliary lipid secretion.
HOXD1	Homeobox protein Hox-D1	Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.
ABO	Histo-blood group ABO system transferase	This protein is the basis of the ABO blood group system.

Protein-family classification

Druggable: 6 · Difficult: 12 · Unknown: 10 · Druggable fraction: 0.21

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Scaffold/PPI	6	3.7×	0.032
Transcription factor	6	1.8×	0.402
Transporter	1	2.8×	0.709
Enzyme (other)	3	1.3×	0.730
Antibody/Immunoglobulin	1	1.0×	0.750
Kinase	1	1.0×	0.750
Other/Unknown	10	0.6×	0.990

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SEMA3E	Antibody/Immunoglobulin	yes		Semap_dom, Ig-like_dom, Immunoglobulin_dom
SURF6	Other/Unknown	no		SURF6, Rrp14/SURF6_C
HNF1B	Transcription factor	no		HD, HNF1b_C, HNF-1_N
TERT	Other/Unknown	no		RT_dom, Telomerase_RT, Telomerase_RBD
TGFBR1	Kinase	yes	2.7.10.2	TGFB_receptor, Activin_recp, Prot_kinase_dom
WNT4	Other/Unknown	no		Wnt, Wnt4, Wnt_CS
ZBTB18	Transcription factor	no		BTB/POZ_dom, SKP1/BTB/POZ_sf, Znf_C2H2_type
SKAP1	Scaffold/PPI	no		SH3_domain, PH_domain, PH-like_dom_sf
MLLT10	Transcription factor	no		Znf_PHD, Znf_FYVE_PHD, Znf_RING/FYVE/PHD
ANKRD30A	Scaffold/PPI	no		Ankyrin_rpt, Ankyrin_rpt-contain_sf, CC144C-like_CC_dom
SRGAP1	Scaffold/PPI	no		RhoGAP_dom, FCH_dom, SH3_domain
NAMPTP1	Other/Unknown	no
SYNPO2	Scaffold/PPI	no		PDZ, PDZ_sf, Synaptopodin_domain
RSPO1	Other/Unknown	no		TSP1_rpt, Furin_repeat, Growth_fac_rcpt_cys_sf
COL15A1	Other/Unknown	no		Collagen, Collagenase_NC10/endostatin, ConA-like_dom_sf
TIPARP	Transcription factor	no	2.4.2.30	Znf_CCCH, WWE_dom, Poly(ADP-ribose)pol_cat_dom
BABAM1	Other/Unknown	no		BABAM1, vWFA_dom_sf
UGT2A2	Other/Unknown	no		UDP_glucos_trans, UDP_glycos_trans_CS, UDP-glycosyltransferase
PLEKHM1	Scaffold/PPI	no		PH_domain, PKC_DAG/PE, Run_dom
ADSS2	Other/Unknown	no		Adenylosuccinate_synthetase, Adenylosuccin_syn_GTP-bd, P-loop_NTPase
WWC1	Scaffold/PPI	no		C2_dom, WW_dom, C2_domain_sf
CHMP4C	Other/Unknown	no		Snf7_fam
BNC2	Transcription factor	no		Znf_C2H2_type, Disconnected-like
AKR1C3	Enzyme (other)	yes	1.1.1.188	Aldo/ket_reductase_CS, AKR, NADP_OxRdtase_dom
ABCB4	Transporter	yes		ABC_transporter-like_ATP-bd, AAA+_ATPase, ABC1_TM_dom
GPX6	Enzyme (other)	yes	1.11.1.9	Glutathione_peroxidase, GPX_AS, GPX_CS
HOXD1	Transcription factor	no		HD, Homeodomain-like_sf, Homeobox_CS
ABO	Enzyme (other)	yes	2.4.1.37	Glyco_trans_6, Nucleotide-diphossugar_trans

Expression context

Cohort genes with no expression data: 0.

23 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	2
broad (>20)	26
unknown	0

Top tissues across cohort

Tissue	Cohort genes
buccal mucosa cell	4
cortical plate	3
right lobe of liver	3
male germ line stem cell (sensu Vertebrata) in testis	3
sural nerve	2
type B pancreatic cell	2
saphenous vein	2
blood	2
germinal epithelium of ovary	2
oocyte	2
secondary oocyte	2
olfactory segment of nasal mucosa	2
jejunal mucosa	2
primordial germ cell in gonad	2
blood vessel layer	1
calcaneal tendon	1
gastrocnemius	1
mucosa of transverse colon	1
adult mammalian kidney	1
kidney	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SEMA3E	197	broad	marker	cortical plate, calcaneal tendon, blood vessel layer
SURF6	134	ubiquitous	marker	sural nerve, mucosa of transverse colon, gastrocnemius
HNF1B	74	broad	marker	metanephros cortex, adult mammalian kidney, kidney
TERT	105	broad	yes	stromal cell of endometrium, type B pancreatic cell, olfactory bulb
TGFBR1	269	ubiquitous	marker	saphenous vein, tibia, visceral pleura
WNT4	177	broad	marker	islet of Langerhans, decidua, type B pancreatic cell
ZBTB18	292	ubiquitous	marker	cerebellar vermis, paraflocculus, cortical plate
SKAP1	189	broad	marker	granulocyte, right lobe of liver, right uterine tube
MLLT10	275	ubiquitous	marker	buccal mucosa cell, adult organism, colonic epithelium
ANKRD30A	69	tissue_specific	marker	epithelium of mammary gland, mammary duct, male germ line stem cell (sensu Vertebrata) in testis
SRGAP1	236	ubiquitous	marker	buccal mucosa cell, cortical plate, medial globus pallidus
NAMPTP1	132		marker	blood, bone marrow cell, bone marrow
SYNPO2	262	ubiquitous	marker	cauda epididymis, saphenous vein, seminal vesicle
RSPO1	129	tissue_specific	yes	endocervix, body of uterus, germinal epithelium of ovary
COL15A1	249	broad	marker	skin of hip, placenta, synovial joint
TIPARP	283	ubiquitous	marker	secondary oocyte, oocyte, upper leg skin
BABAM1	278	ubiquitous	marker	prefrontal cortex, right frontal lobe, anterior cingulate cortex
UGT2A2	17		yes	male germ line stem cell (sensu Vertebrata) in testis, olfactory segment of nasal mucosa, right lobe of liver
PLEKHM1	134	broad	yes	lower esophagus mucosa, esophagus mucosa, blood
ADSS2	285	ubiquitous	marker	monocyte, mononuclear cell, leukocyte
WWC1	268	ubiquitous	marker	ventricular zone, parotid gland, buccal mucosa cell
CHMP4C	196	ubiquitous	marker	amniotic fluid, jejunal mucosa, ileal mucosa
BNC2	229	ubiquitous	marker	germinal epithelium of ovary, sural nerve, parietal pleura
AKR1C3	285	ubiquitous	marker	jejunal mucosa, pancreatic ductal cell, gall bladder
ABCB4	188	broad	marker	right lobe of liver, secondary oocyte, oocyte
GPX6	12	ubiquitous	yes	male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad, olfactory segment of nasal mucosa
HOXD1	185	broad	marker	corpus epididymis, primordial germ cell in gonad, metanephric glomerulus
ABO	169	broad	marker	tendon of biceps brachii, buccal mucosa cell, right lobe of thyroid gland

Protein interactions among cohort

Intra-cohort edges: 2.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TERT	5,717
TGFBR1	4,828
GPX6	3,286
CHMP4C	2,775
ADSS2	2,681
TIPARP	2,481
SURF6	2,470
WNT4	2,347
ABCB4	2,333
RSPO1	2,160

Intra-cohort edges

A	B	Sources
HNF1B	MLLT10	biogrid_interaction, intact
RSPO1	WNT4	string_interaction

Structural data

PDB: 18 · AlphaFold-only: 9 · No structure: 1

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ABO	P16442	151
AKR1C3	P42330	67
TGFBR1	P36897	44
TERT	O14746	23
RSPO1	Q2MKA7	12
MLLT10	P55197	6
PLEKHM1	Q9Y4G2	5
WWC1	Q8IX03	5
SURF6	O75683	4
CHMP4C	Q96CF2	4
ABCB4	P21439	4
HNF1B	P35680	3
BABAM1	Q9NWV8	3
ZBTB18	Q99592	1
SKAP1	Q86WV1	1
ANKRD30A	Q9BXX3	1
COL15A1	P39059	1
ADSS2	P30520	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
UGT2A2	P0DTE5	92.46
WNT4	P56705	91.41
SEMA3E	O15041	84.62
SRGAP1	Q7Z6B7	73.49
TIPARP	Q7Z3E1	70.00
HOXD1	Q9GZZ0	61.63
BNC2	Q6ZN30	54.10
SYNPO2	Q9UMS6	49.86
GPX6	P59796

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 121. Enrichment computed across 28 evidence-associated genes (18 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 18 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Nephron development	2	97.6×	0.022	HNF1B, WNT4
TCF dependent signaling in response to WNT	3	19.6×	0.027	TERT, WNT4, RSPO1
Defective ABCB4 causes PFIC3, ICP3 and GBD1	1	634.4×	0.064	ABCB4
Loss of Function of TGFBR2 in Cancer	1	211.5×	0.084	TGFBR1
TGFBR2 Kinase Domain Mutants in Cancer	1	211.5×	0.084	TGFBR1
TGFBR1 LBD Mutants in Cancer	1	158.6×	0.084	TGFBR1
Loss of Function of TGFBR1 in Cancer	1	126.9×	0.084	TGFBR1
Loss of Function of SMAD2/3 in Cancer	1	105.7×	0.084	TGFBR1
Signaling by TGF-beta Receptor Complex in Cancer	1	105.7×	0.084	TGFBR1
SMAD2/3 Phosphorylation Motif Mutants in Cancer	1	105.7×	0.084	TGFBR1
TGFBR1 KD Mutants in Cancer	1	105.7×	0.084	TGFBR1
Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence	1	90.6×	0.084	TERT
Regulation of gene expression in early pancreatic precursor cells	1	79.3×	0.084	HNF1B
Inactivation of CDC42 and RAC1	1	79.3×	0.084	SRGAP1
TGFBR3 regulates TGF-beta signaling	1	79.3×	0.084	TGFBR1
Deubiquitination	2	13.8×	0.084	TGFBR1, BABAM1
Signaling by WNT	2	12.4×	0.084	TERT, RSPO1
Signal Transduction	6	3.4×	0.084	TERT, TGFBR1, SRGAP1, RSPO1, WWC1, AKR1C3
Purine ribonucleoside monophosphate biosynthesis	1	57.7×	0.103	ADSS2
Synthesis of bile acids and bile salts via 24-hydroxycholesterol	1	48.8×	0.103	AKR1C3
Translation of Replicase and Assembly of the Replication Transcription Complex	1	48.8×	0.103	CHMP4C
Translation of Replicase and Assembly of the Replication Transcription Complex	1	45.3×	0.103	CHMP4C
Glucuronidation	1	42.3×	0.103	UGT2A2
Synthesis of bile acids and bile salts via 27-hydroxycholesterol	1	42.3×	0.103	AKR1C3
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)	1	42.3×	0.103	AKR1C3
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells	1	39.6×	0.103	HNF1B
Negative regulation of TCF-dependent signaling by WNT ligand antagonists	1	39.6×	0.103	WNT4
Transcriptional regulation of testis differentiation	1	39.6×	0.103	WNT4
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	1	37.3×	0.103	TGFBR1
Developmental Lineage of Mammary Gland Alveolar Cells	1	35.2×	0.103	ANKRD30A

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 26 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
kidney development	4	21.6×	0.011	HNF1B, TGFBR1, WNT4, TIPARP
RNA-templated transcription	1	648.1×	0.018	TERT
response to symbiont	1	648.1×	0.018	UGT2A2
DNA strand elongation	1	648.1×	0.018	TERT
female sex determination	1	648.1×	0.018	WNT4
regulation of pronephros size	1	648.1×	0.018	HNF1B
pronephric nephron tubule development	1	648.1×	0.018	HNF1B
extracellular structure organization	1	648.1×	0.018	TGFBR1
macromolecule metabolic process	1	648.1×	0.018	AKR1C3
response to ammonium ion	1	648.1×	0.018	ADSS2
ureteric bud elongation	1	648.1×	0.018	HNF1B
obsolete negative regulation of mesenchymal cell apoptotic process involved in mesonephric nephron morphogenesis	1	648.1×	0.018	HNF1B
negative regulation of testicular blood vessel morphogenesis	1	648.1×	0.018	WNT4
cellular response to prostaglandin stimulus	1	648.1×	0.018	AKR1C3
cellular response to corticosteroid stimulus	1	648.1×	0.018	AKR1C3
metanephric nephron morphogenesis	1	648.1×	0.018	WNT4
siRNA transcription	1	648.1×	0.018	TERT
mesenchymal cell apoptotic process involved in metanephros development	1	648.1×	0.018	HNF1B
positive regulation of transdifferentiation	1	648.1×	0.018	TERT
negative regulation of male gonad development	1	648.1×	0.018	WNT4
positive regulation of cortisol biosynthetic process	1	648.1×	0.018	WNT4
negative regulation of androgen biosynthetic process	1	648.1×	0.018	WNT4
obsolete regulation of Rho-dependent protein serine/threonine kinase activity	1	648.1×	0.018	SYNPO2
late endosome to lysosome transport	2	76.2×	0.018	PLEKHM1, CHMP4C
female gonad development	2	61.7×	0.018	WNT4, TIPARP
skeletal system morphogenesis	2	38.1×	0.018	TGFBR1, TIPARP
roof of mouth development	3	28.6×	0.018	TGFBR1, TIPARP, BNC2
male gonad development	3	18.0×	0.018	TGFBR1, WNT4, AKR1C3
negative regulation of cell migration	3	12.9×	0.018	TGFBR1, WNT4, SRGAP1
positive regulation of Wnt signaling pathway	2	29.5×	0.023	TERT, RSPO1

Therapeutics

Drug target analysis

Approved (phase 4): 4 · Phase ≥3: 4 · Phased (≥1): 5 · Undrugged: 23

Druggability breadth: 8 of 28 evidence-associated genes (29%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TERT	BERBERINE
TGFBR1	MOMELOTINIB
TIPARP	OLAPARIB
AKR1C3	DICLOFENAC SODIUM

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TGFBR1	28	4
AKR1C3	22	4
TERT	10	4
TIPARP	4	4
ABCB4	1	2
SEMA3E	0	0
SURF6	0	0
HNF1B	0	0
WNT4	0	0
ZBTB18	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
BERBERINE	4	AKR1C3, TERT
DOXORUBICIN	4	TERT
MOMELOTINIB	4	TGFBR1
DABRAFENIB	4	TGFBR1
NINTEDANIB	4	TGFBR1
DASATINIB	4	TGFBR1
CRIZOTINIB	4	TGFBR1
OLAPARIB	4	TIPARP
DICLOFENAC SODIUM	4	AKR1C3
DIAZEPAM	4	AKR1C3
BIMATOPROST	4	AKR1C3
GLIMEPIRIDE	4	AKR1C3
NAPROXEN	4	AKR1C3
DEXIBUPROFEN	4	AKR1C3
GLICLAZIDE	4	AKR1C3
MECLOFENAMIC ACID	4	AKR1C3
IBUPROFEN	4	AKR1C3
FLURBIPROFEN	4	AKR1C3
INDOMETHACIN	4	AKR1C3
MEFENAMIC ACID	4	AKR1C3
MEDROXYPROGESTERONE ACETATE	4	AKR1C3
RESVERATROL	3	TERT
EPIGALOCATECHIN GALLATE	3	TERT
PERIFOSINE	3	TERT
SARACATINIB	3	TGFBR1
CANERTINIB	3	TGFBR1
TESEVATINIB	3	TGFBR1
CEDIRANIB	3	TGFBR1
LESTAURTINIB	3	TGFBR1
PAMIPARIB	3	TIPARP

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 5.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
TGFBR1	541	Binding:516, Functional:13, ADMET:12
TERT	391	Binding:389, Functional:2
AKR1C3	204	Binding:197, ADMET:7
TIPARP	48	Binding:48
UGT2A2	35	ADMET:35
ABO	6	Binding:6
ABCB4	4	ADMET:3, Binding:1
ADSS2	2	Binding:2

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
TGFBR1	2.7.10.2, 2.7.11.30	non-specific protein-tyrosine kinase, receptor protein serine/threonine kinase
TIPARP	2.4.2.30	NAD+ ADP-ribosyltransferase
AKR1C3	1.1.1.188, 1.1.1.21, 1.1.1.213, 1.1.1.239, 1.1.1.357, 1.1.1.51, 1.1.1.62, 1.1.1.64, 1.3.1.20	prostaglandin-F synthase, aldose reductase, 3alpha-hydroxysteroid 3-dehydrogenase (Re-specific), 3alpha(17beta)-hydroxysteroid dehydrogenase (NAD+), 3alpha-hydroxysteroid 3-dehydrogenase, 3(or 17)beta-hydroxysteroid dehydrogenase, 17beta-estradiol 17-dehydrogenase, testosterone 17beta-dehydrogenase (NADP+), trans-1,2-dihydrobenzene-1,2-diol dehydrogenase
GPX6	1.11.1.9	glutathione peroxidase
ABO	2.4.1.37, 2.4.1.40, 2.4.1.88	fucosylgalactoside 3-alpha-galactosyltransferase, glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase, globoside alpha-N-acetylgalactosaminyltransferase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TERT	391
TGFBR1	541
AKR1C3	204

Pharmacogenomics

Cohort genes with a PharmGKB record: 27; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

29 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
BERBERINE	4	AKR1C3, TERT
DOXORUBICIN	4	TERT
MOMELOTINIB	4	TGFBR1
DABRAFENIB	4	TGFBR1
NINTEDANIB	4	TGFBR1
DASATINIB	4	TGFBR1
CRIZOTINIB	4	TGFBR1
DICLOFENAC SODIUM	4	AKR1C3
DIAZEPAM	4	AKR1C3
BIMATOPROST	4	AKR1C3
GLIMEPIRIDE	4	AKR1C3
NAPROXEN	4	AKR1C3
DEXIBUPROFEN	4	AKR1C3
GLICLAZIDE	4	AKR1C3
MECLOFENAMIC ACID	4	AKR1C3
IBUPROFEN	4	AKR1C3
FLURBIPROFEN	4	AKR1C3
INDOMETHACIN	4	AKR1C3
MEFENAMIC ACID	4	AKR1C3
MEDROXYPROGESTERONE ACETATE	4	AKR1C3
RESVERATROL	3	TERT
EPIGALOCATECHIN GALLATE	3	TERT
PERIFOSINE	3	TERT
SARACATINIB	3	TGFBR1
CANERTINIB	3	TGFBR1
TESEVATINIB	3	TGFBR1
CEDIRANIB	3	TGFBR1
LESTAURTINIB	3	TGFBR1
PAMIPARIB	3	TIPARP

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	4	TERT, TGFBR1, TIPARP, AKR1C3
B	Phased (≥1) drug, not yet approved	1	ABCB4
C	Druggable family + PDB, no drug	1	ABO
D	Druggable family + AlphaFold only, no drug	2	SEMA3E, GPX6
E	Difficult family or no structure, no drug	20	SURF6, HNF1B, WNT4, ZBTB18, SKAP1, MLLT10, ANKRD30A, SRGAP1, NAMPTP1, SYNPO2 (+10 more)

Undrugged target profiles

23 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
SEMA3E	0	—
SURF6	0	—
HNF1B	0	—
WNT4	0	—
ZBTB18	0	—
SKAP1	0	—
MLLT10	0	—
ANKRD30A	0	—
SRGAP1	0	—
NAMPTP1	0	—
SYNPO2	0	—
RSPO1	0	—
COL15A1	0	—
BABAM1	0	—
UGT2A2	35	—
PLEKHM1	0	—
ADSS2	2	—
WWC1	0	—
CHMP4C	0	—
BNC2	0	—
GPX6	0	—
HOXD1	0	—
ABO	6	—

Clinical trials & evidence

Clinical trials

Clinical trials: 130.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	51
PHASE1	39
Not specified	25
PHASE1/PHASE2	8
PHASE3	4
EARLY_PHASE1	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03349463	PHASE4	UNKNOWN	Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
NCT01376752	PHASE3	ACTIVE_NOT_RECRUITING	Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
NCT00041080	PHASE3	COMPLETED	Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01611766	PHASE3	UNKNOWN	Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
NCT03220932	PHASE3	UNKNOWN	Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer
NCT04055649	PHASE2	RECRUITING	ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
NCT05335993	PHASE2	ACTIVE_NOT_RECRUITING	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
NCT06638931	PHASE2	RECRUITING	Agnostic Therapy in Rare Solid Tumors
NCT07341100	PHASE2	RECRUITING	Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
NCT00006942	PHASE2	COMPLETED	Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00016289	PHASE2	COMPLETED	Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00022659	PHASE2	COMPLETED	Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00023712	PHASE2	COMPLETED	Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00025155	PHASE2	COMPLETED	Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
NCT00026091	PHASE2	COMPLETED	Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
NCT00036751	PHASE2	COMPLETED	Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
NCT00041041	PHASE2	COMPLETED	Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00053365	PHASE2	COMPLETED	Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00059787	PHASE2	COMPLETED	Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
NCT00063895	PHASE1/PHASE2	COMPLETED	Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
NCT00081276	PHASE2	COMPLETED	3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
NCT00083122	PHASE2	COMPLETED	Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00091195	PHASE2	TERMINATED	Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
NCT00093496	PHASE2	COMPLETED	Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
NCT00096395	PHASE2	COMPLETED	Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer
NCT00107445	PHASE2	COMPLETED	EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer
NCT00113373	PHASE2	COMPLETED	Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
NCT00126542	PHASE2	COMPLETED	Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00132067	PHASE2	COMPLETED	Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
NCT00182767	PHASE1/PHASE2	COMPLETED	Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
NCT00275028	PHASE2	COMPLETED	AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00278343	PHASE2	COMPLETED	Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
NCT00313612	PHASE2	TERMINATED	Oxaliplatin and Topotecan in Advance Ovarian Cancer
NCT00316407	PHASE1/PHASE2	COMPLETED	Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients
NCT00334893	PHASE2	COMPLETED	Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
NCT00388037	PHASE2	COMPLETED	Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00390234	PHASE2	COMPLETED	Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
NCT00429793	PHASE2	COMPLETED	Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00436501	PHASE1/PHASE2	COMPLETED	VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00466960	PHASE2	COMPLETED	Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LAPATINIB	4	6
ERLOTINIB	4	3
SORAFENIB	4	3
DENILEUKIN DIFTITOX	4	2
IMATINIB MESYLATE	4	2
IXABEPILONE	4	2
METFORMIN HYDROCHLORIDE	4	2
ONDANSETRON	4	2
TRABECTEDIN	4	2
AURANOFIN	4	1
AVELUMAB	4	1
BELINOSTAT	4	1
CEFEPIME HYDROCHLORIDE	4	1
DEFERASIROX	4	1
ERIBULIN MESYLATE	4	1
FLUCICLOVINE F18	4	1
LITHIUM CARBONATE	4	1
OLAPARIB	4	1
PROPRANOLOL HYDROCHLORIDE	4	1
ROMIDEPSIN	4	1
SUNITINIB MALATE	4	1
TAMOXIFEN CITRATE	4	1
TEMSIROLIMUS	4	1
THALIDOMIDE	4	1
TOPOTECAN	4	1
VORINOSTAT	4	1
ALVOCIDIB	3	3
CEDIRANIB MALEATE	3	2
TRIAPINE	3	2
VELIPARIB	3	2